Compare Amphastar Pharmaceuticals Inc (AMPH) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs RLX Technology Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while RLX Technology Inc trades at $1.98 (market cap $2.44B). The key difference: RLX Technology Inc is far larger — about 2.8× Amphastar Pharmaceuticals Inc's market cap, and RLX Technology Inc pays a 5% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | RLX | |
|---|---|---|
Market Cap | $863.95M | $2.44B |
Sector | Health | Technology |
52-Week High | $30.81 | $2.73 |
52-Week Low | $16.87 | $1.79 |
Enterprise Value | $1.26B | $1.07B |
Dividend Yield | — | 5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
RLX Technology trades at $2.01, up 1.01% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 revenue growth to $4.4B with a net profit margin of 22.47%, though it missed EPS estimates for three consecutive quarters. Recent news highlights international expansion, including European integration and a 70% international revenue share.
Outlook is mixed: strong fundamentals with cash flow from operations and no debt support growth, but earnings misses and regulatory risks in the vaping industry pose challenges. The sole analyst coverage recommends Hold, reflecting cautious optimism amid execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
